High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous...

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Patients with chronic kidney disease (CKD) often exhibit clopidogrel resistance (CR) after percutaneous coronary intervention (PCI).
• Standard clopidogrel dosing may be insufficient in CKD patients with CR, increasing risks of adverse cardiovascular events.
• Optimizing antiplatelet therapy is crucial for improving outcomes in this high-risk population.

Purpose of the Study:

• To evaluate the efficacy and safety of a higher dose of clopidogrel (150 mg/d) compared to standard dose (75 mg/d) in CKD patients with CR post-PCI.
• To assess the impact of 150 mg/d clopidogrel on maximal platelet aggregation (MPA), stent thrombosis (ST), major adverse cardiac events (MACEs), and bleeding.

Main Methods:

• A randomized controlled trial involving 370 CKD patients with CR after PCI.
• Patients received either clopidogrel 75 mg/d or 150 mg/d for 30 days post-PCI.
• Outcomes including MPA, ST, MACEs, and bleeding were assessed at 1-month follow-up.

Main Results:

• The 150 mg/d clopidogrel group showed significantly lower rates of ST and MACE compared to the 75 mg/d group.
• Patients receiving 150 mg/d clopidogrel exhibited lower MPA and greater platelet aggregation inhibition.
• No significant difference in major or minor bleeding events was observed between the two groups.

Conclusions:

• One-month administration of 150 mg/d clopidogrel is effective in reducing ST and MACE in CKD patients with CR after PCI.
• This higher dose regimen improves antiplatelet effect without increasing bleeding complications.
• Higher-dose clopidogrel represents a viable therapeutic option for managing high-risk CKD patients with clopidogrel resistance.